Dornan, David <br/><br/>
Effect of FCGR2A and FCGR3A variants on CLL outcome.  [electronic resource] 

 -  Blood  Nov 2010 
 - 4212-22 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2010-03-272765  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Murine-Derived--pharmacokinetics<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cyclophosphamide--therapeutic use<br/>Disease-Free Survival<br/>Female<br/>Genotype<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--diagnosis<br/>Male<br/>Middle Aged<br/>Polymorphism, Single Nucleotide--genetics<br/>Prognosis<br/>Receptors, IgG--genetics<br/>Rituximab<br/>Treatment Outcome<br/>Vidarabine--analogs & derivatives